Overview
The goal of this observational study is to explore the feasibility of using 18F-labeled FAP molecular probe for PET/CT imaging (18F-FAPI PET/CT) to accurately evaluate inflammation and fibrosis in renal diseases. The main questions it aims to answer are:
- Can 18F-FAPI PET/CT accurately evaluate the inflammation and fibrosis of kidney disease?
- What is the value of 18F-FAPI PET/CT as a non-invasive assessment of inflammation and fibrosis in kidney disease? Participants will receive [18F]AlF-NOTA-FAPI-04 PET/CT and renal aspiration biopsy.
Eligibility
Inclusion Criteria:
- The pitients of nephritis or fibrosis disease
Exclusion Criteria:
- Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg
- Renal biopsy cannot be performed for severe exclotting disease
- Complicated with chronic liver disease, myocardial infarction, stroke, and malignant tumor
- Unable to cooperate with renal puncture biopsy due to language communication or other problems
- Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception
- Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
- Alcohol allergy
- Patients with significant decrease in urine volume due to disease
- Refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved protocol
- Other circumstances deemed inappropriate by the investigator for participation in the study.